Having multiple chronic conditions isn't likely to impact the effectiveness of common medications

Publicly released:
International
Photo by Ksenia Yakovleva on Unsplash
Photo by Ksenia Yakovleva on Unsplash

A range of treatments for various chronic diseases are likely to be just as effective for people with multiple conditions, according to international research. The team say treating chronic health problems can be challenging for people with multiple conditions, because they are often underrepresented in clinical trials. To address, this, the researchers reviewed 120 previous clinical trials and compared data on participants who did have multiple conditions. They say across the 23 conditions studied in those trials, they found no evidence of multiple conditions interacting to reduce the effectiveness of the treatments.

Media release

From: PLOS

Does multimorbidity impact chronic disease treatment?

In new analysis of 120 previous clinical trials, researchers found no evidence that treatment efficacies depend on number of comorbidities

Treatment efficacy for a broad range of chronic diseases does not differ depending on patients’ comorbidities, according to a new study publishing June 6th in the open access journal PLOS Medicine by David McAllister of the University of Glasgow, UK, and colleagues.

There is often uncertainty about how treatments for single conditions should be applied to people who have multiple chronic conditions (multimorbidity). This confusion stems, in part, from the fact that people with multimorbidity are under-represented in randomized controlled trials, and trials rarely report whether the efficacy of treatment differs by the number of comorbidities or the presence of specific comorbidities.

In the new study, the researchers used existing data from 120 industry-sponsored randomized controlled phase 3 and 4 clinical trials carried out between 1990 and 2017. The dataset included a total of 128,331 participants and spanned 23 common long-term conditions, including asthma, diabetes, hypertension, osteoporosis, and migraine. For each trial as well as each treatment type spanning multiple trials, the team modeled whether there were any interactions between treatment efficacy and comorbidities.

Across trials, the percentage of participants with three or more comorbidities ranged from 2.3% (in allergic rhinitis trials) to 57% (in trials for systemic lupus erythematosus). Overall, the new study found no evidence of comorbidities modifying treatment efficacy across any of the 23 conditions studied. However, the authors noted that the trials were not designed to assess variation in treatment efficacy by comorbidity.

“The standard assumption used in evidence syntheses is that efficacy is constant across subgroups, although this is often criticized,” the authors say. “Our findings suggest that for modest levels of comorbidities, this assumption is reasonable.”

Coauthor Peter Hanlon adds, “Many people live with multiple long-term conditions, however deciding on the most appropriate treatment for these people is often challenging because clinical trials rarely report whether treatments work as well in people with multiple conditions and clinical guidelines rarely address the specific needs of these people. We found that treatments had similar effects in people with multiple conditions, which is important as this information can be used to help experts decide which treatments they should recommend in clinical guidelines.”

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research PLOS, Web page The URL will go live after the embargo ends
Journal/
conference:
PLOS Medicine
Research:Paper
Organisation/s: University of Glasgow, UK
Funder: This work was funded by the Wellcome Trust (grant number 201492/Z/16/Z, grant recipients DMA, SD) and the Medical Research Council (grant number MR/S021949/1, grant recipient PH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Media Contact/s
Contact details are only visible to registered journalists.